Digitalis Ventures is a venture capital firm that invests in solutions to complex problems in human and animal health. Digitalis partners with entrepreneurs, scientists, and inventors across all stages of venture investing. The firm comprises technical professionals with deep industry experience and networks in diverse areas related to human and animal health. Through domain expertise and a dedication to the entrepreneurial process, Digitalis is deeply committed to helping their portfolio companies scale their impact on the world.
Location: United States, New York
Employees: 11-50
Founded date: 2016
Investment Type: Venture Capital
Portfolio 36
Date | Name | Website | Total Raised | Location |
30.06.2022 | Faeth Ther... | faeththerapeutics.com | $67M | - |
31.05.2022 | Eden Brew | edenbrew.com.au | $33.5M | Australia,... |
30.04.2022 | Poppins He... | poppinshealth.com | - | United Sta... |
27.01.2022 | findhelp | company.findhelp.com | - | United Sta... |
25.11.2021 | Terray The... | terraytx.com | $180M | United Sta... |
25.11.2021 | Biomilq | biomilq.com | $21M | Philippine... |
07.08.2021 | SeQure | sequre-dx.com | $17.5M | United Sta... |
07.08.2021 | Cayaba Car... | cayabacare.com | $15.2M | United Sta... |
15.06.2021 | Companion ... | companionfund.com | - | - |
12.06.2021 | RiverDog | riverdogdaycare.com | - | United Sta... |
Show more
News 41
Date | Title | Description |
31.03.2022 | Native Pet Scoops Up $6 Million in Series A Funding Led by CAVU Venture Partners | Native Pet, a pet nutrition company that makes all-natural, highly effective, and limited ingredient pet supplements for dogs, announced today the closing of $6 million in Series A funding led by CAVU Venture Partners with participation fro... |
07.01.2022 | PetMedix enters into antibody discovery collaboration with Zoetis | PetMedix™ is pleased to announce a collaboration with Zoetis to develop novel, fully species-specific companion animal monoclonal antibody therapeutics (mAbs) using PetMedix’s proprietary transgenic platforms. As part of the collaboration, ... |
06.01.2022 | Notes on Engineering Health, December 2021 | ICYMI 2021 Edition Another year ends and instead of writing about the many challenges in front of the world at the moment which we thought did not carry a very positive message for the festive season, we decided to look back on the subje... |
25.11.2021 | Notes on Engineering Health, September 2021 | Notes on the Privacy and Security of Electronic Health Information In 2015, the insurance company Anthem announced that they had been hacked and as many as 78.8 million former and current policyholders had personal information stolen. ... |
25.11.2021 | Nucleate: Empowering BioTech Founders | We sat down with Michael Retchin, a graduate student in New York and the co-founder of the Nucleate program, a student-led, entirely nonprofit educational organization that helps academic trainees start companies. Digitalis is an early ... |
25.11.2021 | Notes on Engineering Health, November 2021 | Surprise Billing: A Personal Story Accounts of absurd or tragic interactions with the American healthcare system are common. A growing sub-genre of these stories involves surprise billing—many such overwhelming experiences have been reco... |
25.11.2021 | Notes on Engineering Health, October 2021 | Nucleate: Empowering Biotech Founders We sat down with Michael Retchin, a graduate student in New York and the co-founder of the Nucleate program. Digitalis is an early partner of Nucleate, dedicating time and resources to the program an... |
31.08.2021 | Notes on Engineering Health, August 2021 | Evolution and Public Health What does it take for a virus to create new variants and to evolve into a more deadly foe? If we were to model the probability of a virus gaining a function — e.g., escaping a vaccine, increasing its virulenc... |
30.07.2021 | Notes on Engineering Health, July 2021 | Some Notes on Model Organisms In 1859, Charles Darwin published the first edition of his seminal work On the Origin of Species By Means of Natural Selection or the Preservation of Favoured Races in the Struggle for Life which laid out ... |
29.06.2021 | Notes on Engineering Health, June 2021 | XX Versus XY Does having two X chromosomes set one back when it comes to being understood and treated by the medical profession? The answer seems to be yes in many instances. Here are five striking examples where there are clear differe... |
Show more
Mentions in press and media 27
Date | Title | Description |
23.10.2024 | Alpha-9 Oncology Raises $175M in Series C Financing | Alpha-9 Oncology Inc., a Boston, MA- and Vancouver, Canada-based clinical stage company developing radiopharmaceuticals to meaningfully improve the treatment of people living with cancer, raised $175m in Series C financing. The round was le... |
22.10.2024 | Terray Therapeutics: $120 Million (Series B) Secured To Improve Human Health | Terray Therapeutics, a biotechnology company focused on improving human health by transforming the speed, cost, and success rate of small molecule drug development using computation integrated with novel data at scale, announced Series B fu... |
17.10.2024 | Terray Therapeutics Closes $120M Series B Funding Round | Terray Therapeutics, a Los Angeles, CA-based biotechnology company improving human health by enhancing small molecule drug development, raised $120M in Series B funding. The round was led by Bedford Ridge Capital and existing investor NVent... |
30.07.2024 | BioIVT Appoints Dr. Judith Dunn and Dr. Auro Nair to its Board of Directors | WESTBURY, N.Y., July 30, 2024 /PRNewswire/ -- BioIVT, a global research partner and biospecimen solutions provider for drug and diagnostic development, today announced the appointment of Dr. Judith Dunn and Dr. Auro Nair to its Board of Dir... |
25.07.2024 | GRO Biosciences Secures $60 Million to Revolutionize Gout Treatment** ** | ** In the bustling world of biotechnology, innovation is the lifeblood. GRO Biosciences, or GRObio, has just taken a giant leap forward. The company recently announced the closing of an oversubscribed $60.3 million Series B financing round.... |
19.07.2024 | GRO Biosciences: Protein Therapeutics Company Raises $60 Million In Series B | GRO Biosciences (GRObio), a biotechnology company leveraging synthetic biology to expand the amino acid alphabet and deliver on the promise of protein therapeutics, today announced the closing of an oversubscribed $60.3 million Series B fin... |
21.05.2024 | Expressable Raises $26M in Series B Funding | Expressable, an Austin, TX-based company which specializes in research-based, family-centered speech therapy care, raised $26M in Series B funding. The round was led by HarbourVest Partners, with participation from Digitalis Ventures and ex... |
13.04.2023 | First Ever AI-Powered Dog Playmate, Companion, Raises Additional $6 Million from Lerer Hippeau, Digitalis Ventures and Officially Opens Reservations | Companion, the first ever AI-powered interactive device for dogs, announced that it has raised $6M in additional funding from Lerer Hippeau and Digitalis Ventures alongside opening its product to the public for reservation. The new capital ... |
19.10.2022 | Digitalis Ventures Closes Fourth Fund, at $300M | Digitalis Ventures, a NYC-based venture capital firm, closed of its fourth fund, totaling $300m in commitments. The new capital will be invested in entrepreneurs and researchers developing breakthrough science and technology with the potent... |
07.09.2022 | Roche shells out $250M to acquire Good Therapeutics and its preclinical oncology program | Roche announced Wednesday that it is paying $250 million in cash to acquire Good Therapeutics, a Seattle-based preclinical biotech company. Good has raised a little over $30 million since it was founded in 2016. The company is focused on cy... |
Show more